ID | 111099 |
著者 |
Tokashiki, Natsumi
Tokushima University
Kobayashi, Makoto
Tokushima University
|
キーワード | glucagon secretion
pancreatic α-cells
PKCδ
streptozotocin-induced diabetic mice
|
資料タイプ |
学術雑誌論文
|
抄録 | Accumulating evidence supports the “glucagonocentric hypothesis”, in which antecedent α-cell failure and inhibition of glucagon secretion are responsible for diabetes progression. Protein kinase C (PKC) is involved in glucagon secretion from α-cells, although which PKC isozyme is involved and the mechanism underlying this PKC-regulated glucagon secretion remains unknown. Here, the involvement of PKCδ in the onset and progression of diabetes was elucidated. Immunofluorescence studies revealed that PKCδ was expressed and activated in α-cells of STZ-induced diabetic model mice. Phorbol 12-myristate 13-acetate (PMA) stimulation significantly augmented glucagon secretion from isolated islets. Pre-treatment with quercetin and rottlerin, PKCδ signaling inhibitors, significantly suppressed the PMA-induced elevation of glucagon secretion. While Go6976, a Ca2+ - dependent PKC selective inhibitor did not suppress glucagon secretion. Quercetin suppressed PMA-induced phosphorylation of Tyr311 of PKCδ in isolated islets. However, quercetin itself had no effect on either glucagon secretion or glucagon mRNA expression. Our data suggest that PKCδ signaling inhibitors suppressed glucagon secretion. Elucidation of detailed signaling pathways causing PKCδ activation in the onset and progression of diabetes followed by the augmentation of glucagon secretion could lead to the identification of novel therapeutic target molecules and the development of novel therapeutic drugs for diabetes.
|
掲載誌名 |
The Journal of Medical Investigation
|
ISSN | 13496867
13431420
|
cat書誌ID | AA11166929
AA12022913
|
出版者 | Faculty of Medicine Tokushima University
|
巻 | 64
|
号 | 1-2
|
開始ページ | 122
|
終了ページ | 128
|
並び順 | 122
|
発行日 | 2017-02
|
EDB ID | |
出版社版DOI | |
出版社版URL | |
フルテキストファイル | |
言語 |
eng
|
著者版フラグ |
出版社版
|
部局 |
薬学系
先端酵素学研究所
|